

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1




FIG. 2




FIG. 3

Rapamycin Release from VDF/HFP (84.5/14.5) in
25% EtOH





FIG. 4

Release in 25% Aq. Ethanol for
 21508 + Rapamycin w/ top coat



4 /51

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15





FIG. 16



10 /51

FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22





FIG. 23



13 151

FIG. 24




FIG. 25





FIG. 26






FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42






FIG. 43





24 /51

FIG. 45





FIG. 46



25 /51

FIG. 47





FIG. 48



26 /51

FIG. 49




FIG. 50






FIG. 51



24 /51

FIG. 52



30 /51

FIG. 53





FIG. 54



3-2/51

FIG. 55






FIG. 56




34 /51

FIG. 57




35 /51

FIG. 58



76 /51

FIG. 59



37 /51

FIG. 60






FIG. 61




39 /51

FIG. 62



40 /51


FIG. 63



4) 151

FIG. 64


Inhibition of CA-SMC proliferation by
 sirolimus and topotecan (14 April 2003)



42 /51

FIG. 65


Inhibition of CA-SMC proliferation by
 sirolimus and etoposide (14 April 2003)



43/51

FIG. 66

Inhibition of CA-SMC proliferation by
Panzem



44 /51

FIG. 67

Inhibition of CA-SMC
proliferation by sirolimus






FIG. 68

Inhibition of CA-SMC proliferation by
 Sirolimus and Panzem




46 151

FIG. 69




47 151

FIG. 70



✓/5 151

FIG. 71



44 /51




Figure 72A




Figure 72B




Figure 72C




Figure 73 A




Figure 73 B

51 /51

